Takara Shuzo Co., Inc.

Takara Bio Inc.

Other

Osaka University

Nobuto Koyama

Ikunoshin Kato

Katsushige Ikai

Hiroaki Sagawa

Kiyozo Asada

Tatsuji Enoki

Eiji Nishiyama

Eiji Kobayashi

Takanari Tominaga

Takashi Uemori

Kimikazu Hashino

Hiromu Ohnogi

Hua-Kang Wu

Takashi Ueno

Takeshi Sakai

Michio Hagiya

Hikaru Takakura

Hideto Chono

Fu-Gong Yu

Naoyuki Taniguchi

Yoshimi Sato

Akihiro Kondo

Masanori Takayama

Hiroshi Kobori

Ryo Hirano

Yuji Hashimoto

Kazutoh Takesako

Junichi Mineno

Jun Tomono

Tetsuo Shiba

Fusao Kimizuka

Kaoru Kojima

Eiji Miyoshi

Atsushi Nishikawa

Nobuko Muraki

Yoshito Ihara

Kaoru Inami

Suzu Deguchi

Takatoshi Nakagawa

Hiromi Okuyama

Tomoe Egashira

Toshitake Okui

Yoko Tatsumi

Kahoko Umeda

Motoko Ueda

Kimakazu Hasino

Shinji Okuda

Kikyozo Asada

Wenzhe Li

Miki Odate

Atsushi Shimada

Tatsui Enoki

The N-acetylglucosaminyltransferase III activity is enhanced in a cell carrying retrovirus-origin gag-pol gene and env gene. By constructing a retrovirus vector with the use of the above cell, a retrovirus vector having a modified sugar chain structure can be obtained. The retrovirus vector constructed by this method shows a high infection efficiency particularly in the presence of a functional substance.

Method for producing retrovirus using human producer cells with increased N-acetylglucosaminyltransferase III activity

Polypeptides having an RNase H activity highly useful in genetic engineering; genes encoding these polypeptides; and a process for genetic engineeringly producing these polypeptides.

Thermotolerant ribonuclease H

Disclosed is a means for reducing the expression amount of a FUT8 gene, reducing the expression amount of a FUT8 protein, and/or reducing the expression amount of a product produced by the action of FUT8.

Composition for suppressing the expression of fucosyltransferase

An isolated polypeptide includes the amino acid sequence shown in SEQ. ID No. 13 and an isolated nucleic acid encoding the polypeptide, such as an isolated nucleic acid including the nucleic acid sequence shown in SEQ. ID No. 17. The isolated polypeptide includes two heparin binding polypeptides connected in tandem and the isolated nucleic acid encodes these. The polypeptide and nucleic acid sequences can improve retroviral vector mediated gene transfer efficiency into target cells.

Enhancement of retroviral gene transduction employing polypeptides comprising the fibronectin heparin II binding domain

A polypeptide represented by SEQ. ID No. 13, a polypeptide represented by SEQ. ID No. 30 or functional equivalents thereof and a polypeptide represented by SEQ. ID No. 17.

Method for gene transfer into target cells with retrovirus

Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1): foods, drinks, cosmetics, etc. containing as the active ingredient at least one member selected from the group consisting of the above-mentioned compound, its aldehyde, its hydrate and 2-O-methylated derivatives thereof and soluble sugar compounds containing the above compound. This compound also shows, for example, an apoptosis-inducing activity, a carcinostatic activity and inhibitory activities on the production of active oxygen, lipid peroxide radicals and NO, which makes it useful also as the active ingredient of antioxidants and preservatives.

Use of algae-derived physiologically active substances for treating a carcinomatous disease

The present invention provides a method for increasing the efficiency of gene transfer into target cells with a retrovirus. The transduction is affected by infecting target cells with a retrovirus in the presence of a mixture of a functional material having a retrovirus binding domain, and a second functional material having target cell binding domain. The target cells may be selected from the group of unintentional hematopoietic progenitor cells and erythrocyte precursor, specifically pluripotent stem cells or embryopalstic stem cells.

Polypeptides having the amino acid sequence represented by SEQ ID NO:6 in Sequence Listing or an amino acid sequence derived from the above sequence by at least one of deletion, addition, insertion or substitution of one or more amino acids and showing a thermophilic glucoamylase activity.

Polypeptides having glucoamylase activity

Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose are represented by formula (I):These compositions include foods, drinks, cosmetics, etc. containing as the active ingredient at least one such compound, its aldehyde, its hydrate and 2-O-methylated derivatives thereof and soluble sugar compounds containing the above compound. These compounds show an apoptosis-inducing activity, carcinostatic activity and inhibitory activities on the production of active oxygen, lipid peroxide radicals and NO, which makes them useful also as the active ingredient of antioxidants and preservatives.

Drugs, foods or drinks with the use of algae-derived physiologically active substances

Substances capable of inducing apoptosis

A substance for inducing apoptosis represented by specific formulae. A pharmaceutical composition which can be used for an anticancer agent containing said substance.

Substance for inducing apoptosis

Polypeptides having the amino acid sequence represented by SEQ ID NO:1 or derived therefrom by at least one of deletion, addition, insertion or substitution of one or more amino acids in the above sequence and showing a cellobiohydrolase activity.

Polypeptide having cellobiohydrolase activity

Remedies or preventives for diseases with a need for immunoregulation, diseases with a need for inhibition of inflammation, diseases with a need for regulation of tumor necrosis factor production, diseases with a need for regulation of fungal growth, diseases with a need for regulation of cell adhesion or disease with a deed for induction of heat-shock protein, which contain as the active ingredient at least one compound selected from among cyclopentenone derivatives represented by general formula &lsqb;I&rsqb;, optically active isomers and salts thereof, wherein R and R are the same or different and each represents hydrogen, an aliphatic group, an aromatic group or an aromatic aliphatic group.

Remedies or preventives containing cyclopentenone compounds as the active ingredient

Therapeutic agents

Growing community of inventors

Uji, Japan

Nobuto Koyama